Journal
EMERGING MICROBES & INFECTIONS
Volume 10, Issue 1, Pages 342-355Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/22221751.2021.1887767
Keywords
SARS-CoV-2; spike glycoprotein; DNA vaccine; protein vaccine; non-human primate
Categories
Funding
- Major Science and Technology Projects of Yunnan Province [2019ZF001, 202003AC100003, 202003AF140002]
- CAMS Initiative for Innovative Medicine [2016-I2M-1-019]
- Fundamental Research Funds for the Central Universities [2020HY320001]
Ask authors/readers for more resources
The study developed a COVID-19 vaccine combining DNA and protein components, which induced high level immune responses in animal models. The co-delivery approach showed full protection in immunized animals, indicating its potential as a safe and effective long-term protection strategy for COVID-19.
The current study aims to develop a safe and highly immunogenic COVID-19 vaccine. The novel combination of a DNA vaccine encoding the full-length Spike (S) protein of SARS-CoV-2 and a recombinant S1 protein vaccine induced high level neutralizing antibody and T cell immune responses in both small and large animal models. More significantly, the co-delivery of DNA and protein components at the same time elicited full protection against intratracheal challenge of SARS-CoV-2 viruses in immunized rhesus macaques. As both DNA and protein vaccines have been proven safe in previous human studies, and DNA vaccines are capable of eliciting germinal center B cell development, which is critical for high-affinity memory B cell responses, the DNA and protein co-delivery vaccine approach has great potential to serve as a safe and effective approach to develop COVID-19 vaccines that provide long-term protection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available